We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 25.00 | 14.00 | 36.00 | 25.00 | 25.00 | 25.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.86 | 37.33M |
RNS No 8202u CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 18th December 1997 Cambridge Antibody Technology Group plc and ICOS Corporation Announce Research and Product Collaboration Cambridge Antibody Technology ("CAT") (LSE : CAT) and ICOS Corporation ("ICOS") (NASDAQ : ICOS), announced today that they have signed a collaborative agreement to develop jointly antibody-based therapeutics to treat diseases and conditions such as inflammation, cancer and allergy. ICOS will contribute certain intellectual property, biological information and expertise relating to six targets, that may be well suited for antibody therapy. CAT will contribute antibody engineering expertise, together with the use of its proprietary target validation and discovery technologies, including the ProxiMol(TM) platform. The parties intend to develop jointly antibody-based human therapeutics and to discover novel associated drug targets. CAT and ICOS will each bear their own costs in the research stage, and will seek to develop commercialisation strategies that share development costs, and the value derived from the collaboration, equally. In addition, ICOS will access CAT's proprietary antibody engineering platform, the Antibody Engine(TM), to select and engineer lead clinical antibody candidates for two undisclosed targets. CAT will receive development funding and, potentially, development milestones and royalties. "This collaboration with ICOS significantly enhances CAT's access to proprietary disease targets, and provides the potential to strengthen further our product pipeline", said Dr. David Chiswell, Chief Executive Officer of CAT. "Importantly, this collaboration with ICOS underpins the launch of our new ProxiMol(TM) platform, part of our suite of powerful functional genomics tools." "By combining the discovery work initiated at ICOS with the human antibody engineering expertise at Cambridge Antibody Technology, we have a fine opportunity here to accelerate product development", commented Dr. George Rathmann, Chairman, President and Chief Executive Officer of ICOS. CAT is a biotechnology company, based in the United Kingdom, which is developing a diverse portfolio of antibody-based human therapeutic products. Its product development programmes include potential treatments for inflammatory disorders, fibrosis and fibrotic diseases, cancer, and obesity. CAT's foundation is a world-leading platform technology for the high-throughput isolation of human monoclonal antibodies. The technology's speed and capacity make it particularly valuable in the field of functional genomics. ICOS is discovering and developing new pharmaceuticals by seeking points of intervention in the inflammatory process that may lead to specific and efficacious drugs. ICOS' research and drug development programs include both acute and chronic conditions such as acute respiratory distress syndrome, acute pancreatitis, asthma, haemorrhagic shock, male erectile disorder, multiple sclerosis, myocardial infarction, and psoriasis. The Company has Phase 1 and Phase 2 clinical trials active in seven indications. For further information please contact: Cambridge Antibody Technology 01763 263 233 David Chiswell Chief Executive Officer John Aston Finance Director Ludgate Communications 0171 253 2252 Andrew Nicolls Notes for Editors: Cambridge Antibody Technology Group plc CAT floated on the London Stock Exchange in March 1997, raising #41 million. CAT's business is based on a world leading platform technology for the rapid isolation of human monoclonal antibodies. This technology has applications both in the development of antibody-based human therapeutic products and as a drug discovery tool, particularly in the context of functional genomics. CAT's strategy is to capitalise on the strength of its platform technology in order to build a diverse portfolio of antibody-based human therapeutic products. Clinical trials of two human monoclonal antibodies developed by CAT have already started in 1997. Phase I/IIa Trials of CAT's anti-TGFb2 monoclonal antibody in patients with early proliferative vitreo retinopathy have recently commenced, and earlier this year Phase I/IIa trials of human anti-TNFa monoclonal antibody isolated and developed by CAT in collaboration with Knoll (BASF) were initiated by Knoll in patients with rheumatoid arthritis. CAT's partner, Techniclone, announced recently that it had received FDA allowance to begin Phase I Clinical Trials with a radiolabelled chimaeric TNT antibody for the treatment of malignant glioma (the most common primary malignant brain tumour). CAT has already entered into a number of licence and collaborative agreements with pharmaceutical and biotechnology companies. These include: technology licenses with Genentech, Pfizer and Eli Lilly; therapeutic antibody licenses with Knoll (BASF), Knoll (BASF)/Genetics Institute and Mitsubishi Chemical; joint ventures with Techniclone and ObeSys (with BTG); and a licence agreement with Integra Life Sciences. The speed and capacity of CAT's platform technology make it particularly valuable in the field of functional genomics, in which biological meaning is extracted from the mass of raw sequence data being created by research into the human genome. In the last year, the CAT(TM) Library has more than quadrupled in size and now incorporates over 67 billion distinct antibodies. The quality of CAT's antibody phage libraries underpins both its functional genomics and product development strategies. ProAb(TM) and ProxiMol(TM) are new technologies developed by CAT. ProAb(TM) is the name given to a proprietary approach to building a database of information on the biological and disease relevance of novel genes. In the same way that genomics companies can sequence every gene in the human genome, CAT can select antibodies against the protein or peptide encoded by each and every gene and partial gene sequence. The ProAb(TM) approach is to screen such antibody probes against a panel of normal and diseased tissues, in a high-throughput manner, identifying 'guilt-by-association'. This allows CAT researchers to focus resources on those protein targets, out of the many thousands listed in genomics databases, that have relevance in a particular disease state. ProxiMol(TM) is so called because it identifies antibodies that bind to other molecules in close proximity to an original protein target. It is used for orphan ligand or receptor matching, elucidation of novel protein - protein interactions, and for identifying the functional epitopes of a protein target. ICOS Corporation ICOS Corporation is a biopharmaceutical company founded to develop novel drugs for the treatment of chronic and acute inflammatory conditions. The Company was co-founded in 1989 by Dr. George Rathmann, founder, former Chairman and Chief Executive Officer, and currently Chairman Emeritus of Amgen, now the largest biotechnology company in the world. One of ICOS' principal scientific strengths is its expertise in cell and molecular biology, and it is renowned for the quality of its scientific staff and management. ICOS employs approximately 250 people, of which 88% work in research and development. At 11 December, 1997 ICOS had a market capitalisation of approximately US$660 million. The Company's objective is to target the earliest stages of the inflammatory process, seeking points of intervention which may lead to more specific and efficacious drugs. The primary strategy is to identify therapeutic targets through a broad understanding of underlying mechanisms and molecular entities involved in inflammatory processes. ICOS believes this strategy will lead to new biological and small molecule pharmaceuticals which may be used to treat diseases. ICOS Development Programmes Hu23F2G is being evaluated in four Phase 2 clinical trials for acute exacerbations of multiple sclerosis, haemorrhagic shock, ischemic stroke and myocardial infarction. Hu23F2G is a humanised monoclonal antibody that has been shown to bind to CD11/CD18 on the surface of white blood cells and to block subsequent movement into the surrounding tissue. Two Phase 2 clinical trials with the recombinant form of a naturally occurring human enzyme, PAF-AH, are underway in ARDS and asthma. PAF-AH converts a potent pro-inflammatory mediator, platelet-activating factor, to a biologically inactive form thereby limiting its effects. Additional Phase 2 trials are being planned in pancreatitis. Early this year, a Phase 1 clinical trial was initiated with a humanised monoclonal antibody, called ICM3, in patients with severe psoriasis. ICM3 has been shown by ICOS scientists to block the function of human ICAM-3, a protein known to facilitate the interactions between two immune cell types, T-cells and antigen presenting cells. ICOS is positioned to begin Phase 2 trials this year with IC351, a PDE-5 inhibitor, for the treatment of male erectile dysfunction. This is a novel phosphodiesterase (PDE) inhibitor that regulates intracellular signal transduction thereby effecting the dilation of blood vessels. END MSCGLMMZGRNLNMG
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions